Kamada (KMDA) Non-Current Debt (2012 - 2023)

Kamada's (KMDA) quarterly Non-Current Debt came in at $10.7 million in Q2 2023, up 90526.05% quarter-over-quarter from $11852.0 in Q1 2023.

Analysis

Kamada (KMDA) Non-Current Debt (2012 - 2023) Analysis & Trends

Kamada (KMDA) has reported Non-Current Debt for 2 consecutive years, with $10.7 million the latest figure, recorded in Q2 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	57.30 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	26.25 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	1.99 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	-
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	591.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	-
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	7.29 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	-
10	Kamada	473.57 Mn	403.43 Mn	22.47 Mn	-

Historic Data

Download Data